{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:53:11Z","timestamp":1772581991727,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[1995,5,1]],"date-time":"1995-05-01T00:00:00Z","timestamp":799286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1995,5]]},"abstract":"<jats:p>The activity of the novel triazole SCH 51048 was tested against Coccidioides immitis. SCH 51048 inhibited C. immitis in vitro; MICs for 13 isolates ranged from &lt; or = 0.39 to 0.78 micrograms\/ml, and minimum fungicidal concentrations ranged from &lt; or = 0.39 to 1.6 micrograms\/ml. In vivo, no mice treated with SCH 51048 at 2 to 50 mg\/kg of body weight or 100 mg of fluconazole or itraconazole per kg died of systemic coccidioidomycosis, whereas 60 to 100% of the control mice died. SCH 51048 given at 25 or 50 mg\/kg was curative, whereas fluconazole or itraconazole given at 100 mg\/kg was not curative. Pharmacokinetic studies showed peak levels in serum of &gt; 14 micrograms\/ml, with an estimated half-life of &gt; 12 h. SCH 51048 was 5- to 50-fold or more superior to fluconazole or itraconazole.<\/jats:p>","DOI":"10.1128\/aac.39.5.1169","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:06:25Z","timestamp":1340841985000},"page":"1169-1172","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo"],"prefix":"10.1128","volume":"39","author":[{"given":"K V","family":"Clemons","sequence":"first","affiliation":[{"name":"California Institute for Medical Research, Santa Clara Valley Medical Center, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Homola","sequence":"additional","affiliation":[{"name":"California Institute for Medical Research, Santa Clara Valley Medical Center, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Stevens","sequence":"additional","affiliation":[{"name":"California Institute for Medical Research, Santa Clara Valley Medical Center, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.39.5.1169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.39.5.1169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:59:45Z","timestamp":1645473585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.39.5.1169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,5]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1995,5]]}},"alternative-id":["10.1128\/AAC.39.5.1169"],"URL":"https:\/\/doi.org\/10.1128\/aac.39.5.1169","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,5]]},"assertion":[{"value":"1995-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}